Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$221,841Cash on Hand
3.5mo Cash Runway
Follow HKPD by emailGet an email when HKPD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HKPD, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Listing Cellyan Biotechnology received a Nasdaq letter on November 13, 2026 confirming it regained compliance with the $1.00 minimum bid price requirement, after its Class A shares closed at or above $1.00 for 14 consecutive business days from October 26 through November 12, 2026. The matter is closed. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Leadership Chairman Lap Sun Wong and independent director Zhao Letao resigned on November 10, 2026, citing no disagreement with the company. Shu Liu, the CFO, was appointed executive director, and Xiaohu Quan was appointed independent director effective November 11, 2026. The Chairman office is now vacant. Form 6-K · SEC filing
Oct 21, 2026 ·
Listing Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) expects to implement a 1-for-20 reverse stock split effective at market open on October 26, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement. Every twenty Ordinary Shares will become one, with a new CUSIP of G6365B112. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Leadership Independent director Mike Yao Zhou resigned from the board and all committee roles, effective September 18, 2026. The board appointed Letao Zhao as an independent director the same day, with committee memberships and chairmanship of the Compensation Committee. Form 6-K · SEC filing
Sep 23, 2026 ·
Shareholder vote Shareholders approved a 1-for-20 share consolidation of Class A and Class B ordinary shares, raising par value from US$0.001 to US$0.02, effective on the date confirmed by Nasdaq. A fifth amended memorandum and articles of association was also approved, conditional on the consolidation. Form 6-K · SEC filing
Sep 10, 2026 ·
Shareholder vote Shareholders will vote at an extraordinary general meeting on September 21, 2026 on a 1-for-20 share consolidation of Class A and Class B ordinary shares, effective on a date confirmed by Nasdaq, along with a related amendment to the company's memorandum and articles of association. Record date is September 9, 2026. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
HKPD holds $221,841 in cash and short-term investments and burns about $187,901/quarter from operations,
an estimated runway of 3.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway not available
Shelf registration (F-3, Jun 2026) +10
Going-concern doubt in the latest 20-F +15These factors raise substantial doubts about the Company’s ability to continue as a going concern.20-F, Aug 2026
Share count +49% in a year +14
Recent financing filings on SEC EDGAR:
Jun 12, 2026 · Shelf registration, up to $200M · F-3
Share count 16,349,986 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HKPD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HKPD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.